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Purpose: The purpose of this study was to review the natural history and clinical outcome of patients with infrainguinal
autogenous graft infection (IAGI), to evaluate the effectiveness of attempted graft preservation, to determine those
variables associated with graft salvage, and to better determine optimal treatment.
Study design: We retrospectively reviewed the records of patients undergoing infrageniculate vein grafts at three hospi-
tals between 1994 and 2000 who had a wound infection involving the graft. Clinical and bacteriologic variables were
analyzed and correlated with graft salvage, limb salvage, and clinical outcome.
Results: During this 7-year period, 487 patients underwent an infrageniculate vein graft, and 68 (13%) had clinical evi-
dence of IAGI. Twenty-seven patients presented with drainage from the wound, 15 with wound separation and cel-
lulitis, 18 with soft tissue infection extending to the graft, 4 with an abscess and cellulitis, and 4 with bleeding. Ten
patients (15%) had systemic symptoms (defined as a white blood cell count > 15,000 and temperature > 38.5°C). Forty
infections developed in the thigh, 17 in the groin, and 11 in the lower leg. An anastomosis was exposed in 15 patients.
Wound cultures were positive for bacteria in 52 patients, and most infections were due to Staphylococcus aureus (18
patients) and S epidermidis (12 patients). Pseudomonas was cultured from seven infections. Twelve patients had polymi-
crobial infections. The interval from operation to infection ranged from 7 to 180 days. All patients were treated with
oral antibiotics, 48 after intravenous antibiotics. Forty-five patients had operative debridement, including 18 who had
muscle flap coverage. Four patients presented with hemorrhage, and three had immediate graft ligation and one graft
excision. Follow-up ranged from 5 to 68 months (mean, 24.3 months), with 61 patients currently alive. Two patients
died as a result of the IAGI (mortality rate, 2.9%). One had undergone a below-knee amputation, and one had a non-
healed wound but intact limb. Overall, 61 wounds (91%) healed, 4 patients required below-knee amputations, and 3
wounds did not heal. Fifty-eight grafts remained patent, 6 thrombosed, and 4 were ligated to control hemorrhage. Of
the 61 wounds that healed, the time required for healing ranged from 7 to 63 days. No patient with bleeding died
because of the acute episode. No patient had delayed hemorrhage. All 18 patients treated with a muscle flap healed.
Bleeding (P < .001), elevated white blood cell count (P < .029), fever (P < .001), and renal insufficiency (creatinine
level > 1.5; P < .056) were the only variables statistically significant in predicting graft failure or limb loss. With the
use of life-table analysis, graft patency was 94%, 72%, and 72% at 1, 3, and 5 years, and limb salvage was 97%, 92%,
and 92% at the same intervals, respectively.
Conclusions: Most patients with an IAGI can be successfully treated with graft and limb preservation. In contrast to
earlier studies, an exposed anastomosis, interval to infection, or Pseudomonas infection is not associated with graft fail-
ure. Graft salvage is less likely in patinets with fever, leukocytosis, and renal insufficency, but because most grafts
remained patent, graft preservation is recommended for these patients. Graft ligation or excision should be reserved
for patients presenting with bleeding or sepsis. (J Vasc Surg 2001;33:948-54.)
Treatment of infrainguinal autogenous graft infection
(IAGI) has evolved in recent years,1 reflecting improve-
ments in antibiotics, wound care, and more liberal use of
local or distant free tissue transfer. Concurrently, a better
understanding of factors predisposing to successful graft
preservation has prompted some authors to recommend
attempted graft preservation, rather than the traditional
treatment of graft ligation and excision.1 This multi-
institutional review was undertaken to review the natural
history, patency, and clinical outcome of patients with
infected infrainguinal autogenous grafts; evaluate the
effectiveness of attempted graft preservation; define those
variables associated with graft salvage; and develop guide-
lines for optimal treatment.
METHODS AND MATERIALS
Patient population. From 1994 to 2000, 487
patients underwent autogenous lower extremity arterial
reconstruction by the authors at a university hospital and
two university-affiliated teaching institutions. Of this
group, 68 (13%) patients (50 male, 18 female) had clini-
cal evidence of a wound infection involving the graft.
Thirty-five (51%) patients had undergone more than one
previous ipsilateral infrainguinal bypass graft, and seven
(10%) patients had undergone a prior inflow procedure.
No patient had a previous ipsilateral, contralateral, or
proximal graft infection, and no patient had a major
amputation (below-knee amputation [BKA] or above-
knee amputation) on the affected side. Eleven (16%)
patients had one or more graft revisions before the identi-
fication of the graft infection. The interval to graft infec-
tion was determined from the date of bypass graft
construction and not the most recent revision. No graft
was thrombosed at the time of IAGI diagnosis.
Diagnosis of an IAGI was made on the basis of estab-
lished clinical criteria.2 These include the presence of an
exposed graft, purulence or a contiguous sinus extending
to the bypass graft, anastomotic disruption or pseudo-
aneurysm formation, graft hemorrhage, or adjacent soft
tissue sepsis. Patients with mild superficial erythema,
suture reaction, or minimal wound separation without
graft exposure were not included in this study.
An appropriate culture of the wound or perigraft fluid
was taken from patients who met these criteria. Blood cul-
tures were obtained from febrile patients. Sonication was
used in some cases of suspected Staphylococcus epidermidis
infection to disrupt the bacterial biofilm to enhance the
recovery of S epidermidis, because routinely obtained cul-
tures will often not identify this organism.
The indication for the initial operation was limb-
threatening ischemia in 45 (66%) patients and disabling
claudication in 23 (34%). All grafts were composed of
autogenous vein and were placed subcutaneously to allow
for easier surveillance and repair. Nineteen (28%) patients
had an open wound or foot infection at the time of graft
placement. All patients received prophylactic antibiotics.
Cefazolin sodium (Kefzol) was given preferentially, with
vancomycin reserved for individuals allergic to cephalo-
sporin. Antibiotics were continued for 3 days and were
continued longer for patients with an open wound or dis-
tal infection.
Study design. During this 7-year period, uniform cri-
teria were used for diagnosis, and several basic therapeutic
principles were used. All patients in whom IAGI was diag-
nosed, as defined by the specified criteria and without
active hemorrhage, were treated with attempted graft
preservation. No patient underwent prophylactic revision
of a patent bypass graft. Graft ligation or excision was only
used to control hemorrhage and was not used as a treat-
ment for patients presenting with systemic sepsis or exten-
sive soft tissue infection.
After identification of a potential graft infection,
wound cultures were obtained and empiric treatment ini-
tiated. Patients underwent drainage of an abscess or fluid
collection; debridement of gangrenous, nonviable, or
grossly infected tissue; and wound irrigation. Wet to damp
dressings were instituted twice daily, and patients were
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kept hospitalized to allow for accurate wound surveillance,
repeated debridements, and intravenous antibiotics.
Debridements were performed either at the bedside or in
the operating room depending on the extent of infection,
need for adjunctive treatment, and potential for urgent
complications such as graft rupture. When feasible, a
blood pressure cuff was placed around the proximal thigh
as long as the graft was exposed to allow for rapid inflation
if hemorrhage started. Broad spectrum antibiotics were
started and were modified according to culture results.
Intravenous antibiotics were continued for a 14-day
period, and patients then received oral antibiotics for an
additional 28 days.
Coverage of an exposed graft with noninfected muscle
or myocutaneous flaps was encouraged. These procedures
were reserved for patients with extensive graft exposure, for
patients with large soft tissue defects, or for patients unable
to undergo the necessary treatment to allow for healing by
second intention. Local and free tissue transfer was used
depending on the extent and location of infection.
Follow-up. Follow-up of patients with an IAGI
included clinical examination and graft duplex evaluation
on the basis of our preestablished protocol. Studies were
obtained every 3 months for the first 2 years, then every 6
months thereafter.
Statistical analysis. Patient demographic informa-
tion, clinical parameters, and bacteriologic results were
statistically analyzed with multiple regression analysis to
determine their effect on outcome. Statistical comparisons
between groups were made with the Fisher exact t test.
Failure was defined as (1) graft thrombosis, ligation, or
excision; (2) residual infection or a nonhealed perigraft
wound; (3) major amputation (BKA or above-knee ampu-
tation), or (4) patients dying because of the graft infec-
tion. The life-table method was used to determine graft
patency and limb salvage. Results were analyzed and
reported in accordance with the reporting standards for
lower extremity arterial reconstructions developed by the
Society for Vascular Surgery/American Association for
Vascular Surgery.3 Statistical significance was defined as a
P value less than .05.
RESULTS
Patient presentation. From 1994 to 2000, 68
patients had clinical evidence of a wound infection involv-
ing the graft. All 68 patients had local findings suggesting
potential bypass graft infection. Twenty-seven patients
presented with wound drainage, 15 with wound separa-
tion and cellulitis, 18 with soft tissue infection surround-
ing the graft, 4 with an abscess and cellulitis, and 4 with
graft hemorrhage. Ten (15%) patients had a white blood
cell count more than 15,000 and temperature more than
38.5°C. No patient, however, was in shock or had other
signs or symptoms of systemic sepsis. Forty infections
developed in the thigh, 17 in the groin, and 11 in the
lower leg. The infection appeared to be confined to a
localized area of the graft in 61 (90%) patients and, 
on subsequent examination and debridement, clinically
involved in the entire graft in only seven (10%) patients. In
53 (78%) patients, the infection did not extend to involve
either anastomosis. An anastomosis was exposed in 15
(22%) patients. The interval from placement of the graft to
presentation with the infection ranged from 7 to 180 days,
and 62 (91%) occurred within 30 days.
Wound or tissue cultures were obtained in all patients
and were positive for bacteria in 52 (76%) individuals. The
bacteria identified are listed in Table I. Twelve patients
had polymicrobial infections. No patients who healed their
graft and wound infection subsequently had a recurrent
infection of the same bypass graft.
Treatment. All patients were initially hospitalized,
and 48 (71%) received intravenous antibiotics. Twenty
patients had organisms identified for which adequate tis-
sue levels of appropriate antibiotics could be obtained
orally. The patients immediately began taking oral antibi-
otics. The duration of intravenous antibiotic treatment
was 14 days, although some patients received a longer
course because of persistent perigraft infection or contin-
ued fevers. All patients received oral antibiotics, with a
standard duration of therapy of 4 weeks. Patients with a
poorly healing wound, underlying immunosuppression, or
a distal lower extremity infection continued taking antibi-
otics indefinitely. Wound debridement was performed in
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all patients. Thirty-one patients underwent multiple
debridements.
Fifty wounds were allowed to heal by second inten-
tion, and local or free muscle transfer was used in 18
patients. Local rotational flaps were used in 15 patients
and free flaps in three. The sartorius or gastrocnemius
muscle was usually used for local flaps, and the rectus
abdominis muscle for free flaps. The choice of type of flap
depended on the location of the infection within the leg
and the availability of muscle for local flap coverage. Free
tissue transfer was used increasingly during the latter part
of this review, as our experience and expertise increased
and as it became apparent that early muscle coverage was
effective in controlling infection, shortening hospitaliza-
tion, and expediting wound healing. No patient required
further debridement after muscle flap placement in the
wound. Seventeen of the 18 patients were discharged
within 1 week of the myocutaneous tissue transfer. No
patient had a hemorrhage while undergoing treatment.
Four patients presented with graft disruption and
bleeding, one at an anastomosis and three from the body
of the graft. One case occurred in the groin and three in
the thigh, and none followed wound debridement. Three
patients had immediate graft ligation, and one had graft
excision. No patient died because of the acute hemor-
rhage. None of the four had attempted rerouting or revi-
sion of the bypass graft, and none underwent a subsequent
ipsilateral vascular reconstruction.
Follow-up. Follow-up ranged from 5 to 68 months
after diagnosis of the IAGI. Mean follow-up was 24
months. All patients were followed up to the present.
Sixty-one (91%) patients are alive, and seven (9%) died.
Two (3%) of the deaths were caused by multiple organ sys-
tem failure resulting from persistent graft infection, and
neither patient had undergone graft ligation. Sixty-one
(91%) wounds healed, four patients underwent major
amputation either for persistent infection or critical
ischemia after graft ligation or excision, and three wounds
remain nonhealed. Fifty-eight (85%) grafts remained
patent, 6 (9%) thrombosed, 3 (4%) were ligated to control
bleeding (including the 3 that presented with hemor-
rhage), and 1 (2%) was excised because of hemorrhage.
With life-table analysis, graft patency was 94%, 72%, and
72% at 1, 3, and 5 years, respectively (Appendix I, online
only; Fig 1). Three patients healed their wounds with suc-
Fig 1. Life-table plot of assisted primary patency for 68 IAGIs. Fig 2. Life-table plot of limb salvage in 68 patients with an IAGI.
Table I. Bacteria cultured from 68 wound infections
involving IAGIs*
Monomicrobial Polymicrobial
Bacteria infection† infection‡
Staphylcoccus aureus 15 18
S epidermidis 11 12
Enterococcus 7 9
Pseudomonas 5 7
Diphtheroids 0 9
Enterobacter 1 2
Escherichia coli 1 1
Group A streptococci 0 1
Klebsiella 0 1
Serratia 0 3
*Fifty-two infections had bacteria cultured, and 16 infections were culture
negative.
†Forty patients.
‡Twelve patients, 63 bacteria isolated.
cessful resolution of the infection but ultimately required
a BKA despite a patent graft. Overall limb salvage was 92%
and was 97%, 92%, and 92% at 1, 3, and 5 years, respec-
tively (Appendix II, online only; Fig 2).
The time required for wound healing ranged from 7
to 63 days. Sixty-two (91%) wounds healed within 30
days, although this included the 18 patients treated with
myocutaneous coverage.
Effect of independent variables on outcome. Demo-
graphic variables, clinical parameters, and bacteriologic
findings were statistically analyzed to determine their effect
on wound healing and graft salvage (Table II). No patient
presenting with bleeding from the graft or graft disruption
underwent attempted graft salvage. Impaired renal func-
tion, leukocytosis, and fever were statistically significant in
predicting failure (defined as either graft thrombosis or
incomplete wound healing). Fever and leukocytosis did not
correlate with the specific organism cultured. The use of
myocutaneous tissue transfer was effective in preserving
graft patency and obtaining adequate wound healing in all
patients in whom it was used, but did not obtain statistical
significance because it was used in only 18 patients.
However, no other variable was statistically significant in
predicting failure of attempted graft salvage.
DISCUSSION
Incidence of graft infection. Despite improvements
in wound care, bypass graft technique, and antibiotics, the
incidence of graft infections and wound complications
after infrainguinal arterial reconstruction has not changed
significantly in recent years. Wound complications will
develop in 10% to 40% of patients,4 and for those patients
with a subcutaneously placed graft, up to 15% will have an
infection extending to the graft.4,5
In contrast to other reports, our study population had
a relatively high incidence of wound infections involving
the graft (13%), but a low subsequent mortality rate attrib-
utable to the infection (3%).6,7 Several factors may partially
explain these findings. Because all of our grafts were placed
subcutaneously, superficial wound complications may be
more likely to infect the graft. Studies about subcuta-
neously placed bypass grafts have invariably reported
higher graft infection rates than studies about anatomically
tunneled bypass grafts. In addition, a substantial number of
our patients were undergoing reoperations or had under-
gone previous bypass graft revision, both of which increase
the infection risk.
Additionally, some of the grafts that met established
clinical criteria for infection may not have been infected.
Calligaro et al,8 Perler et al,9 and others reported that it is
difficult to separate true graft infections from “wound
problems” that involve the graft. The infection, sinus, or
abscess, although extending to the graft, may not result in
a graft infection. Wound problems developing in the early
postoperative period are less likely to represent true graft
infections compared with wound problems occurring
later.11 However, attempting to determine if the graft was
actually infected, without removing and culturing the
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bypass graft, is impossible. Because many surgeons are
appropriately concerned about graft rupture as a conse-
quence of an inadequately treated graft infection, poten-
tially infected grafts have often been treated the same as
grafts known to be infected. These patients were included
in this study because graft infection could not be
excluded, and we wanted to determine if even potentially
infected grafts, with surrounding infection, could be sal-
vaged. Finally, 16 patients had tissue and wound cultures
that showed no growth, although this may represent
either a false-negative culture or a noninfectious inflam-
matory process. The possibility that not all of the grafts
were actually infected is further supported by the low
morbidity and mortality rate in our series, 7.3%, compared
with 7% to 80% major morbidity rate (death or amputa-
tion) in other reports.
Complications and treatment of IAGI. Graft
preservation offers several potential advantages over rou-
tine graft excision. Graft excision is often a technically dif-
ficult procedure, and a new bypass graft may be required
to avoid amputation, which has an increased risk of
becoming infected.1,6 Graft preservation eliminates the
need for a major operation with associated anesthetic risks,
does not require placement of a new bypass graft, and
results in almost universal limb salvage as long as the graft
remains patent.1,6 Calligaro et al8 noted that most patients
who died of uncontrolled graft sepsis or hemorrhage had
undergone complete graft excision, with subsequent rup-
ture of the native artery. Graft preservation also reduces
the risk of blowout of the patch used to repair the native
artery. Studies in which graft preservation was used have
reported amputation rates of 3% to 8%,10,11 although
mortality rates have still ranged from 10% to 22%.1,4,9,10
With routine graft preservation, our overall incidence
of major complications was 7.3%, which reflected four
patients requiring BKA (one of whom died of the infec-
tion) and one additional death from IAGI. Overall, two
patients died of infection, one of whom had undergone
amputation. Our favorable amputation rate of 5.8% and
mortality rate of 3% may therefore reflect (1) the manage-
ment approach used; (2) the fact some grafts, despite the
Table II. Effect of demographic variables, clinical 
parameters, and bacteriologic findings on graft failure 
or limb loss (outcome)
Variable P value
Bleeding at presentation .00
Fever (> 38.5°C) .001
Fever and leukocytosis (WBC > 15,000) .012
Renal insufficiency .056
Myocutaneous tissue transfer .103
Diabetes .257
Hypertension .475
Exposed anastomosis .486
Cardiac disease .664
WBC, White blood cell count.
presence of surrounding infection, may not have been
infected, or (3) the liberal use of myocutaneous coverage.
However, in other reports investigators have found that
infected thrombosed grafts or grafts in patients presenting
with systemic sepsis are rarely successfully salvaged, and
attempted graft presentation often results in major com-
plications. No graft in our series met either of these con-
ditions. Others have reported that graft preservation is
more likely to be successful for patients with infections,
appearing within 2 months of operation.8 More than 90%
of the patients in our study presented within this time
period, and this may also partly explain our success with
graft preservation. Caution is therefore advised in inter-
preting the benefits of our treatment approach and deter-
mining indications for graft preservation.
Indications for attempted graft preservation. This
series confirms the benefits of attempted graft preservation
as opposed to the traditional approach of graft ligation or
excision. Given these advantages, it then becomes impor-
tant to identify the clinical and bacteriologic parameters
that indicate when graft preservation should or should not
be attempted.
In previous studies it was noted that gram-negative
infections and specifically Pseudomonas infections have a
high risk of graft disruption and should be treated with
graft excision.10,11 Calligaro et al10 noted, however, that
some Pseudomonas infections heal, and in our experience
with seven such patients, Pseudomonas did not predispose
to graft rupture or major complications. However, we
advise caution in interpreting these results on the basis of
only seven patients. This may represent a type II statistical
error. Nevertheless, routine excision of a Pseudomonas-
infected graft may not be warranted.
Muscle flaps were helpful in reducing the incidence of
complications, and we support their early use when possi-
ble. Investigators have found that placing healthy muscle
over the infected wound may not only prevent graft dessi-
cation and rupture, but may also promote healing of the
wound and treatment of the infection.5,9 None of the 18
patients in our study treated with a muscle flap had a
major complication, and all of the grafts remained patent.
The flaps facilitated earlier discharge, reduced the need for
repeated debridements, and provided significant cost sav-
ings. No patient required further debridements after the
myocutaneous tissue transfer, and more than 90% were
discharged within 1 week. Others have also reported that
muscle flaps reduce the incidence of complications,
although graft rupture and death may still result.4
The appropriate duration of antibiotic treatment has
not been determined. Some authors have recommended 6
weeks of intravenous antibiotics,8 but our experience sug-
gests that many grafts can be salvaged with a much shorter
course. The presence of systemic signs of infection, repeat
culture results, and the time required for complete graft
coverage with no residual clinical evidence of infection
may influence the required treatment. In addition, the
role of subsequent oral antibiotics is also controversial,
with some reports suggesting that oral antibiotics are not
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required; other investigators state that they are used rou-
tinely.8 We have been concerned about residual infection
and, therefore, have used them for all patients.
Recommendations for treatment. Our experience
suggests the following approach to patients presenting
with an IAGI. For patients with a patent graft, no evidence
of systemic sepsis, and no graft hemorrhage, graft preser-
vation should be attempted. Patients should be hospital-
ized and the wound debrided of all nonviable, infected, or
necrotic tissue. Wound and tissue cultures should be
obtained. Wet to damp dressings should be placed in the
wound and over the graft to prevent dessication and rup-
ture. Intravenous antibiotics should be started, unless pre-
viously obtained cultures have identified organisms that
are susceptable to oral antibiotics and the appropriate oral
antibiotics can provide adequate tissue concentrations.
Repeated debridements should be performed as necessary,
and the intravenous antibiotics should be continued for at
least 2 weeks unless there is residual infection or compli-
cations develop.
Myocutaneous tissue coverage should be obtained as
soon as possible, and it does not need to be deferred until
there is complete absence of residual infection. Oral
antibiotics should be started after completion of the
course of intravenous therapy and should be continued for
4 weeks after all evidence of infection has subsided.
Routine graft surveillance with duplex scan, in association
with regular follow-up clinical examinations, should help
to ensure graft patency.
Because this study was not randomized, firm conclu-
sions about the appropriate length of intravenous antibi-
otic treatment, the benefit of myocutaneous tissue
transfer, or the role of oral antibiotics cannot be reliably
determined. Individual clinical judgment is critical,
because patients not responding to this course of therapy
may require graft ligation to prevent hemorrhage. This
protocol cannot be applied to grafts that are thrombosed,
patients presenting with hemorrhage from the graft, or
patients with systemic sepsis, because this study does not
provide data in these situations.
CONCLUSION
This study represents one of the largest experiences
with IAGIs and is the only recent report attempting to val-
idate proposed criteria for graft preservation. It represents
a multi-institutional review with defined clinical criteria for
infection. In addition, given the limitations of a retrospec-
tive review and the potential for type II errors, our study
provides support for the concept of attempted graft preser-
vation unless the patient presents with graft disruption or
bleeding, graft thrombosis, or sepsis. The presence of an
exposed anastomosis, interval to infection, and identifica-
tion of Pseudomonas does not portend failure for this
approach. The presence of renal insufficiency, fever, and
leukocytosis may result in a higher failure rate, but should
not preclude attempts at graft preservation. Myocutaneous
tissue transfer should be used when possible, and its rou-
tine use may further reduce the risk of major complica-
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tions. Our overall death and complication rates compare
favorably with that reported for routine graft excision and
suggests routine excision may not be justifiable for most
patients with IAGI.
We wish to thank Christine Gazak for her assistance
with statistical analysis.
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DISCUSSION
Dr Linda M. Reilly (San Francisco, Calif). Well, I only have
two concerns with this report: I don’t think that you were treat-
ing graft infections, and I don’t think that your data support your
conclusions. Aside from that, I thought it was a nice series with
good results.
With regard to the definition of infection, these are autoge-
nous grafts. Why is the infection rate higher than what is com-
monly reported for prosthetic grafts? Are your inclusion criteria
overly broad? You report “adjacent soft tissue sepsis” as a criterion
of graft infection. While this may be appropriate for prosthetic
grafts, can you really assume that the vein conduit is infected if
there is adjacent soft tissue infection? How many grafts were actu-
ally exposed either at the time of presentation or after debride-
ment? In fact, 91% of your infections manifested in the
perioperative period (ie, within 30 days). Therefore, I consider
this to be a series of acute wound problems after autogenous
grafting. In these circumstances, the graft is an innocent
bystander to the soft tissue problem. If the soft tissue problem is
handled appropriately, salvage of the graft is to be expected.
With regard to your conclusions, you summarize by saying
that your series proves the benefits of graft preservation as
opposed to the traditional approach of graft ligation and excision.
Well, no it doesn’t since there is no traditional treatment group in
your series. In addition, I would dispute that graft ligation and
excision is the traditional treatment modality for these patients,
with autogenous conduits.
You then go on to list the factors that did not correlate with
successful or unsuccessful graft preservation, such as nature of the
organism, an exposed anastomosis, and muscle flaps. Since 97% of
patients survived, 91% of wounds healed, 85% of grafts remained
patent (actually 91% when you eliminate the 4 that were deliber-
ately ligated), and 92% of limbs were preserved, how can you with
any confidence eliminate any variable as not predictive of any of
these rarely occurring events? Are we not seeing a type II error
with regard to the variables that you claim have no relationship to
the success of your treatment?
I also have a few miscellaneous questions. Since 62% of your
grafts were femoropopliteals and since, as you acknowledge, the
infection rate for subcutaneously placed grafts is higher than for
anatomically or deeply placed grafts and since the amount of the
remaining femoropopliteal graft that is truly subcutaneous is
maybe only one third to one half of the conduit, why are you
placing these grafts subcutaneously?
Why include the ligated and excised grafts as failures? You
made no attempt to save these grafts, and the ligation/excision
was mandated by the nature of the presentation (bleeding). I
think that you are stretching the point here. The loss of the graft
is due to the infection. The limb loss associated with graft liga-
tion/excision without reconstruction will still be counted as an
adverse event, including the fact that the ligation/excision may
have influenced your statistical analysis.
Do you have any thoughts about the fact that almost 60% of
the infections manifested in the thigh? Which flaps were used?
How many of the exposed anastomoses were covered with flaps?
You have cited a number of articles in your discussion that
actually have little relevance to your series. Several of these series
(Mertens, Cherry, Kitka, Perler) included no or very few vein
grafts; rather, they were series of infected prosthetic infrainguinal
grafts. I think you need to be very cautious about extrapolating
the data from infected prosthetic grafts to infected autogenous
grafts. Our approach to these two problems is directly opposite:
we preserve autogenous grafts and remove prosthetic ones.
The authors present a nice series that actually describes the
course of wound complications after autogenous infrainguinal
bypass. The results should provide treatment guidelines for oth-
ers and provide reassurance that early appearing wound compli-
cations, even when they result in exposure and/or infection of
autogenous conduits, do not lead inexorably to loss of graft, limb,
or life. The results should not be applied to chronic prosthetic
graft infection. One also needs to be very cautious in applying this
approach to the most difficult situation involving autogenous
conduits, specifically, presentation with bleeding.
Dr Gerald S. Treiman. I thank Dr Reilly for her comments
and specific questions.
She is not sure all of the wound infections are true graft infec-
tions. I agree with that premise. It is impossible to prove. We use
the established clinical criteria based on all the papers and per-
taining references that we can find. How someone can prove
before bleeding or thrombosis that an exposed graft in an exposed
wound or with surrounding infection is or is not infected is
impossible to determine unless you culture the graft.
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She wants to know why the infection rate is higher than for
prosthetic grafts. I think that it reflects two things. Number one,
it may reflect the criteria that the different authors used for defin-
ing their own criteria for infection. Others may say that if they
have surrounding soft tissue sepsis or an abscess that their graft is
not infected and, therefore, they would come out with a lower
infection rate.
Number two, I think the fact that our grafts are all placed
subcutaneously results in a potentially higher infection rate than
grafts that are tunnel deep, and the trade-off for that is we get
much easier surveillance and repair.
She asked for the number of grafts that were exposed and
that was presented within the manuscript.
She comes to the conclusion, which may be accurate, that
many of these represent acute wound problems rather than graft
infections. That may be true, and I think, trying to separate an
abscess surrounding a bypass from an abscess with an infected
bypass before anything happens is very difficult, but I think the
safest thing to do is to attempt to treat them for a potential graft
infection and recognize that you can treat the wound problem
and potentially the graft problem successfully without ligating the
bypass and without a risk of major complications.
In conclusion, she says that we can’t prove our conclusion
regarding the importance of independent variables. We don’t
claim to prove that any of those variables necessarily portend suc-
cess or failure or that our conclusions are definitive. All we were
attempting to show is that a lot of the preestablished concerns
regarding, for example, exposed anastomoses, Pseudomonas infec-
tions, systemic sepsis, large abscess, and extensive exposed graft,
which may very well represent a graft infection, do not necessar-
ily mean that you need to ligate the bypass.
She asked how certain we can be that different variables really
are or are not significant because it may represent a type II error.
She is correct; this may represent a type II error.
She said 62% of the grafts were femoropopliteals. Why do we
place them subcutaneously? Once again, it’s for our duplex sur-
veillance and for repair.
She asked if we changed our approach. The answer is occa-
sionally we will tunnel them deeper. If they go above the knee,
we usually tunnel them deep. If they go below the knee, it
depends.
She questioned the benefit of routine follow-up. We have had
tremendous success using routine duplex and repair in keeping
these grafts patent. I am a very strong believer in routine follow-
up of these grafts.
She asks why do we include the ligated or the excised grafts
as treatment failure since there was no attempt to preserve them.
What we were attempting to do is just find all of the patients that
presented in our experience with a graft infection or with evi-
dence of one of these clinical parameters. So, therefore, by includ-
ing all of them we have to include the ones that we ligate initially.
Now, it is true that theoretically you could say they are not
necessarily treatment failures. More important, they don’t alter
the fundamental conclusion we come to that is aside from patients
presenting hemorrhage, you can attempt to salvage almost all of
these grafts.
She asked us why 60% occurred in the thigh and why they’re
focal. The number of grafts passing through the thigh is higher
than the number in the leg, since none of the femoropopliteals
reach the calves. That’s probably the best reason I can come up
with. As to why they’re focal, I think that just depends on the
extent of debridement and how early you catch the infection.
She asked about the number of flaps we used. We used 18
flaps. She asked about how many of the anastomoses exposed
were flaps. In general, we made more of an effort to cover an
anastomosis than an exposed graft. I can’t tell you how many of
the actual anastomoses got covered with free tissue transfer other
than to say that any of the ones that seemed to have significant
exposure, those with significant soft tissue defects, and those that
might have benefited from flaps were treated with flaps if we
thought the patient was a suitable candidate and if the microvas-
cular surgeon concurred.
In fact, indications for salvage of a vein graft and for a pros-
thetic graft may turn out to be different, and I don’t want to con-
clude that this paper provides the definitive information on
indication for salvage of a vein graft, but I would at least suggest
it provides reasonable clinical parameters that can be used and
that are not currently otherwise available.
AVAILABILITY OF JOURNAL BACK ISSUES
As a service to our subscribers, copies of back issues of Journal of Vascular Surgery for the preceding
5 years are maintained and are available for purchase from Mosby until inventory is depleted. The fol-
lowing quantity discounts are available: 25% off on quantities of 12 to 23, and one third off on quanti-
ties of 24 or more. Please write to Mosby, Subscription Customer Service, 6277 Sea Harbor Dr, Orlando,
FL 32887, or call 800-654-2452 or 407-345-4000 for information on availability of particular issues. If
unavailable from the publisher, photocopies of complete issues may be purchased from Bell & Howell
Information and Learning, 300 N Zeeb Rd, Ann Arbor, MI 48106-1346, or call 734-761-4700 or 800-
521-0600.
